Mercaptopurine Silver Pharma

Mercaptopurine, the active ingredient in Mercaptopurine Silver Pharma, is a purine analog antimetabolite presented as a strength/form for oral use. It treats acute lymphoblastic leukemia, is employed in maintenance therapy for leukemia, and serves as an immunosuppressant in inflammatory bowel disease.

GNH USA supplies Mercaptopurine Silver Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Mercaptopurine is used in diseases where abnormal cell proliferation or immune activation is a key factor.

Acute lymphoblastic leukemia (ALL): used as part of induction and maintenance regimens to achieve and sustain remission. Maintenance therapy for leukemia: helps prevent relapse by suppressing residual malignant cells. Inflammatory bowel disease (IBD): employed as an immunosuppressive agent to reduce intestinal inflammation in Crohn’s disease and ulcerative colitis.

Adverse reactions may occur and should be monitored during therapy.

Common Side Effects: - Nausea or vomiting - Loss of appetite - Mild leukopenia or neutropenia - Fatigue - Rash or mild skin irritation - Elevated liver enzymes

Serious or Rare Side Effects: - Severe bone‑marrow suppression (pancytopenia) - Hepatotoxicity or liver failure - Pancreatitis - Severe infections due to immunosuppression - Hypersensitivity reactions including Stevens‑Johnson syndrome - Secondary malignancies such as therapy‑related leukemia

Before initiating therapy, clinicians should assess baseline parameters and monitor patients regularly.

Monitor blood counts: perform regular CBC to detect myelosuppression. Assess liver function: schedule periodic LFTs for hepatotoxicity. Screen for infections: watch for signs of opportunistic infection. Avoid use in patients with known hypersensitivity to mercaptopurine. Pregnancy and lactation: prescribe only if potential benefits outweigh risks. Store at below 25°C: keep in the original container, protect from moisture and light.

Mercaptopurine may interact with several medicines, requiring dose adjustments or avoidance.

Major Interactions (Avoid): - Allopurinol: can markedly increase mercaptopurine toxicity. - Azathioprine: additive myelosuppressive effect. - Warfarin: may enhance anticoagulant activity and increase bleeding risk.

Moderate Interactions (Monitor Closely): - TPMT inhibitors: require dose reduction based on enzyme activity. - Fluoroquinolones: may raise risk of bone‑marrow suppression. - Methotrexate: combined immunosuppression may necessitate closer laboratory monitoring.